Summary
Biotechnology in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Synopsis
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Asia-Pacific
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Asia-Pacific
- Leading company profiles reveal details of key biotechnology market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific biotechnology market with five year forecasts
Reasons To Buy
- What was the size of the Asia-Pacific biotechnology market by value in 2016?
- What will be the size of the Asia-Pacific biotechnology market in 2021?
- What factors are affecting the strength of competition in the Asia-Pacific biotechnology market?
- How has the market performed over the last five years?
- What are the main segments that make up Asia-Pacific's biotechnology market?
Key Highlights
The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
The Asia-Pacific biotechnology market is expected to generate total revenues of $86.8bn in 2016, representing a compound annual growth rate (CAGR) of 6% between 2012 and 2016.
The Medical/Healthcare segment is expected to be the market's most lucrative in 2016, with total revenues of $47.2bn, equivalent to 54.4% of the market's overall value.
Japan continues to be the most valuable biotechnology in the Asia-Pacific region, leading to investment which will continue the strong recent performances of the industry. Biotechnology in Japan is unusually balanced; most countries biotech industry is heavily weighted in favor of medicine and healthcare.
'
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Astellas Pharma Inc.
Merck and Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Takeda Pharmaceutical Company Limited
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
Table 1: Asia-Pacific biotechnology industry value: $ billion, 2012-16(e)
Table 2: Asia-Pacific biotechnology industry category segmentation: $ billion, 2016(e)
Table 3: Asia-Pacific biotechnology industry geography segmentation: $ billion, 2016(e)
Table 4: Asia-Pacific biotechnology industry value forecast: $ billion, 2016-21
Table 5: Astellas Pharma Inc.: key facts
Table 6: Astellas Pharma Inc.: key financials ($)
Table 7: Astellas Pharma Inc.: key financials (¥)
Table 8: Astellas Pharma Inc.: key financial ratios
Table 9: Merck and Co., Inc.: key facts
Table 10: Merck and Co., Inc.: key financials ($)
Table 11: Merck and Co., Inc.: key financial ratios
Table 12: Mitsubishi Tanabe Pharma Corporation: key facts
Table 13: Mitsubishi Tanabe Pharma Corporation: key financials ($)
Table 14: Mitsubishi Tanabe Pharma Corporation: key financials (¥)
Table 15: Mitsubishi Tanabe Pharma Corporation: key financial ratios
Table 16: Takeda Pharmaceutical Company Limited: key facts
Table 17: Takeda Pharmaceutical Company Limited: key financials ($)
Table 18: Takeda Pharmaceutical Company Limited: key financials (¥)
Table 19: Takeda Pharmaceutical Company Limited: key financial ratios
Astellas Pharma Inc.
Merck and Co., Inc.
Mitsubishi Tanabe Pharma Corporation
Takeda Pharmaceutical Company Limited
